Maine CDC Health Advisory
November 30, 2022
Deauthorization of Bebtelovimab Treatment for COVID-19
FDA today revoked the emergency use authorization for bebtelovimab, a monoclonal antibody therapy. Accordingly, bebtelovimab may no longer be used for COVID-19 treatment in the U.S. With the continued appearance of new variants, COVID-19 infection is now likely to be due to variants resistant to all monoclonal antibody therapies. Healthcare facilities offering COVID-19 monoclonal antibody treatment should explore offering Veklury to patients who cannot receive Paxlovid and should retain outpatient infusion capacity for COVID-19 monoclonal antibody therapies that could be authorized later.